CAMP4 Therapeutics Corporation (CAMP)
NASDAQ:CAMP
CAMP Stock Chart & Stats
$4.49
-$0.13(-2.84%)
At close: 4:00 PM EST
$4.49
-$0.13(-2.84%)
Day’s Range― - ―
52-Week Range$1.31 - $7.75
Previous Close$4.45
Volume38.22K
Average Volume (3M)310.73K
Market Cap
$233.12M
Enterprise Value-$8.99M
Total Cash (Recent Filing)$109.52M
Total Debt (Recent Filing)$1.97M
Price to Earnings (P/E)―
Beta1.84
Next Earnings
May 19, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.86
Shares Outstanding51,919,320
10 Day Avg. Volume67,256
30 Day Avg. Volume310,729
Financial Highlights & Ratios
PEG Ratio6.16
Price to Book (P/B)3.90
Price to Sales (P/S)53.24
P/FCF Ratio-6.24
Enterprise Value/Market Cap-0.04
Enterprise Value/Revenue-2.57
Enterprise Value/Gross Profit-3.32
Enterprise Value/Ebitda0.17
Forecast
1Y Price Target
$9.00Price Target Upside100.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.78
Revenue Forecast (FY)$4.09M
Bulls Say, Bears Say
Bulls Say
Clinical DifferentiationCMP-002's antisense approach aims to restore SYNGAP1 expression and is potentially disease modifying, offering benefits across multiple symptoms beyond seizures and reinforcing its position as a differentiated lead candidate.
Financial ResourcesUpfront payment and the recent private placement materially strengthen the company's cash position, supporting expansion of the planned clinical study and funding near-term development milestones.
Strategic CollaborationsStrategic collaboration with a major pharmaceutical partner validates the company's regulatory RNA-targeting platform and increases attractiveness for additional partner deals.
Bears Say
Clinical Development RiskKey aspects of the clinical plan, including study design and target patient population, remain to be finalized, creating execution and regulatory uncertainty for upcoming trials.
Collaborations PaceLimited internal capacity could constrain the number of new external collaborations that can be executed concurrently, delaying potential deal-driven development opportunities.
Management StrategyManagement emphasis on prioritizing internal programs may slow the pursuit of multiple external partnerships and limit collaborative growth.
CAMP4 Therapeutics Corporation News
CAMP FAQ
What was CAMP4 Therapeutics Corporation’s price range in the past 12 months?
CAMP4 Therapeutics Corporation lowest stock price was $1.30 and its highest was $7.75 in the past 12 months.
What is CAMP4 Therapeutics Corporation’s market cap?
CAMP4 Therapeutics Corporation’s market cap is $233.12M.
When is CAMP4 Therapeutics Corporation’s upcoming earnings report date?
CAMP4 Therapeutics Corporation’s upcoming earnings report date is May 19, 2026 which is in 35 days.
How were CAMP4 Therapeutics Corporation’s earnings last quarter?
CAMP4 Therapeutics Corporation released its earnings results on Mar 26, 2026. The company reported -$0.86 earnings per share for the quarter, missing the consensus estimate of -$0.473 by -$0.387.
Is CAMP4 Therapeutics Corporation overvalued?
According to Wall Street analysts CAMP4 Therapeutics Corporation’s price is currently Undervalued.
Does CAMP4 Therapeutics Corporation pay dividends?
CAMP4 Therapeutics Corporation does not currently pay dividends.
What is CAMP4 Therapeutics Corporation’s EPS estimate?
CAMP4 Therapeutics Corporation’s EPS estimate is -0.21.
How many shares outstanding does CAMP4 Therapeutics Corporation have?
CAMP4 Therapeutics Corporation has 51,919,320 shares outstanding.
What happened to CAMP4 Therapeutics Corporation’s price movement after its last earnings report?
CAMP4 Therapeutics Corporation reported an EPS of -$0.86 in its last earnings report, missing expectations of -$0.473. Following the earnings report the stock price went down -5.482%.
Which hedge fund is a major shareholder of CAMP4 Therapeutics Corporation?
Currently, no hedge funds are holding shares in CAMP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CAMP4 Therapeutics Corporation Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.00 (100.45% Upside)
$9.00 (100.45% Upside)
Blogger Sentiment
Bullish
CAMP Sentiment 70%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 6.5%
Last 30 Days ▼ 6.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
113.80%
12-Months-Change
Fundamentals
Return on Equity
-162.49%
Trailing 12-Months
Asset Growth
50.44%
Trailing 12-Months
Company Description
CAMP4 Therapeutics Corporation
CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.
CAMP Stock 12 Month Forecast
Average Price Target
$9.00
▲(100.45% Upside)
Technical Analysis
Relmada Therapeutics
―
Beyondspring
―
MiNK Therapeutics
―
Artiva Biotherapeutics, Inc.
―
OS Therapies Incorporated
―
Ownership Overview
28.09% Insiders
4.72% Mutual Funds
41.76% Other Institutional Investors
22.61% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---